- Home
- GHRS vs ZVRA Comparison
GHRS vs ZVRA Comparison
Compare GHRS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- ZVRA
- Stock Information
- Founded
- GHRS 2018
- ZVRA 2006
- Country
- GHRS Ireland
- ZVRA United States
- Employees
- GHRS N/A
- ZVRA N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- ZVRA Health Care
- Exchange
- GHRS Nasdaq
- ZVRA Nasdaq
- Market Cap
- GHRS 462.0M
- ZVRA 458.5M
- IPO Year
- GHRS 2021
- ZVRA 2015
- Fundamental
- Price
- GHRS $8.99
- ZVRA $8.15
- Analyst Decision
- GHRS Strong Buy
- ZVRA Strong Buy
- Analyst Count
- GHRS 3
- ZVRA 7
- Target Price
- GHRS $35.67
- ZVRA $21.20
- AVG Volume (30 Days)
- GHRS 89.4K
- ZVRA 492.6K
- Earning Date
- GHRS 02-27-2025
- ZVRA 11-12-2024
- Dividend Yield
- GHRS N/A
- ZVRA N/A
- EPS Growth
- GHRS N/A
- ZVRA N/A
- EPS
- GHRS N/A
- ZVRA N/A
- Revenue
- GHRS N/A
- ZVRA $24,489,000.00
- Revenue This Year
- GHRS N/A
- ZVRA N/A
- Revenue Next Year
- GHRS N/A
- ZVRA $384.62
- P/E Ratio
- GHRS N/A
- ZVRA N/A
- Revenue Growth
- GHRS N/A
- ZVRA 47.85
- 52 Week Low
- GHRS $5.92
- ZVRA $4.20
- 52 Week High
- GHRS $14.99
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- GHRS 58.18
- ZVRA 45.71
- Support Level
- GHRS $8.02
- ZVRA $7.61
- Resistance Level
- GHRS $10.23
- ZVRA $8.10
- Average True Range (ATR)
- GHRS 0.90
- ZVRA 0.37
- MACD
- GHRS 0.11
- ZVRA -0.02
- Stochastic Oscillator
- GHRS 62.20
- ZVRA 40.30
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.